Trimetazidine normalizes postischemic function of hypertrophied rat hearts

Journal of Pharmacology and Experimental Therapeutics

Volumn 314, Issue 1, 2005, Pages 446-454

  Saeedi, Ramesh ^a   Grist, Mark ^a   Wambolt, Richard B ^a   Bescond Jacquet, Anne ^b   Lucien, Arnaud ^b   Allard, Michael F ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LACTIC ACID; PALMITIC ACID; TRIMETAZIDINE;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FUNCTION; HEART HYPERTROPHY; HEART MUSCLE ISCHEMIA; HYPOTHESIS; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; CARDIOMEGALY; CORONARY CIRCULATION; GLUCOSE; GLYCOLYSIS; KINETICS; LACTIC ACID; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATION-REDUCTION; PALMITATES; PERFUSION; PROTONS; RATS; RATS, SPRAGUE-DAWLEY; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 23044498436     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.082636     Document Type: Article

References (40)

1. Allard MF, Schonekess BO, Henning SL, English DR, and Lopaschuk GD (1994) Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am J Physiol 267:H742-H750.
2. Allibardi S, Chierchia SL, Margonato V, Merati G, Neri G, Dell'Antonio G, and Samaja M (1998) Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. Cardiovasc Drugs Ther 12:543-549.
3. Anderson PG, Allard MF, Thomas GD, Bishop SP, and Digerness SB (1990) Increased ischemic injury but decreased hypoxic injury in hypertrophied rat hearts. Circ Res 67:948-959.
4. Anonymous (2000) Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy; a double-blind, placebo-controlled, randomized trial. The EMIP-FR Group. European Myocardial Infarction Project-Free Radicals. Eur Heart J 21:1537-1546.
5. Benjamin EJ and Levy D (1999) Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 317:168-175.
6. Boucher FR, Hearse DJ, and Opie LH (1994) Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 24:45-49.
7. Burelle Y, Wambolt RB, Grist M, Parsons HL, Chow JC, Antler C, Bonen A, Keller A, Dunaway GA, Popov KM, et al. (2004) Regular exercise is associated with a protective metabolic phenotype in the rat heart. Am J Physiol Heart Circ Physiol 287:H1055-H1063.
8. Chiolero RL, Revelly JP, Leverve X, Gersbach P, Cayeux MC, Berger MM, and Tappy L (2000) Effects of cardiogenic shock on lactate and glucose metabolism after heart surgery. Crit Care Med 28:3784-3791.
9. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP, and Gropler RJ (2002) Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 40:271-277.
10. Dizon J, Burkhoff D, Tauskela J, Whang J, Cannon P, and Katz J (1998) Metabolic inhibition in the perfused rat heart: evidence for glycolytic requirement for normal sodium homeostasis. Am J Physiol 274:H1082-H1089.
11. El Banani H, Bernard M, Baetz D, Cabanes E, Cozzone P, Lucien A, and Feuvray D (2000) Changes in intracellular sodium and pH during ischaemia-reperfusion are attenuated by trimetazidine. Comparison between low- and zero-flow ischaemia. Cardiovasc Res 47:688-696.
12. El Banani H, Bernard M, Cozzone P, James F, and Feuvray D (1998) Ionic and metabolic imbalance as potential factors of ischemia reperfusion injury. Am J Cardiol 82:25K-29K.
13. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, et al. (1992) The heart in hypertension. N Engl J Med 327:998-1008.
14. Guarnieri C and Muscari C (1993) Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 46:324-331.
15. Hajri T, Ibrahimi A, Coburn CT, Knapp FF Jr, Kurtz T, Pravenec M, and Abumrad NA (2001) Defective fatty acid uptake in the spontaneously hypertensive rat is a primary determinant of altered glucose metabolism, hyperinsulinemia and myocardial hypertrophy. J Biol Chem 276:23661-23666.
16. Hata K, Takasago T, Saeki A, Nishioka T, and Goto Y (1994) Stunned myocardium after rapid correction of acidosis. Increased oxygen cost of contractility and the role of the Na(+)-H+ exchange system. Circ Res 74:794-805.
17. Hochachka PW and Mommsen TP (1983) Protons and anaerobiosis. Science (Wash DC) 219:1391-1397.
18. Jeremy RW, Ambrosio G, Pike MM, Jacobus WE, and Becker LC (1993) The functional recovery of post-ischemic myocardium requires glycolysis during early reperfusion. J Mol Cell Cardiol 25:261-276.
19. Kannel WB (2000) Fifty years of Framingham Study contributions to understanding hypertension. J Hum Hypertens 14:83-90.
20. Kantor PF, Lucien A, Kozak R, and Lopaschuk GD (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86:580-588.
21. Lavanchy N, Martin J, and Rossi A (1987) Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 286:97-110.
22. Liu Q, Docherty JC, Rendell JC, Clanachan AS, and Lopaschuk GD (2002) High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in postischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 39:718-725.
23. Lopaschuk GD, Barr R, Thomas PD, and Dyck JR (2003) Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 93:e33-e37.
24. Lopaschuk GD, Collins-Nakai R, Olley PM, Montague TJ, McNeil G, Gayle M, Penkoske P, and Finegan BA (1994) Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J 128:61-67.
25. Lopaschuk GD, Wambolt RB, and Barr RL (1993) An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J Pharmacol Exp Ther 264:135-144.
26. MacInnes A, Fairman DA, Binding P, Rhodes J, Wyatt MJ, Phelan A, Haddock PS, and Karran EH (2003) The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 93:e26-e32.
27. Nascimben L, Ingwall JS, Lorell BH, Pinz I, Schultz V, Tornheim K, and Tian R (2004) Mechanisms for increased glycolysis in the hypertrophied rat heart. Hypertension 44:662-667.
28. Rahman F, Toshima Y, Kohno H, Kinoshita K, and Tokunaga K (1989) The protective effects of trimetazidine on normothermic ischemic myocardium in rats. Jpn J Surg 19:346-350.
29. Sack MN, Rader TA, Park S, Bastin J, McCune SA, and Kelly DP (1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94:2837-2842.
30. Sambandam N, Lopaschuk GD, Brownsey RW, and Allard MF (2002) Energy metabolism in the hypertrophied heart. Heart Fail Rev 7:161-173.
31. Schreiber W, Herkner H, Koreny M, Bur A, Hirschl MM, Glogar D, Huber K, and Laggner AN (2002) Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support. Resuscitation 55:269-276.
32. Stanley WC, Lopaschuk GD, Hall JL, and McCormack JG (1997) Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res 33:243-257.
33. Stanley WC and Marzilli M (2003) Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. Fundam Clin Pharmacol 17:133-145.
34. Steg PG, Grollier G, Gallay P, Morice M, Karrillon GJ, Benamer H, Kempf C, Laperche T, Arnaud P, Sellier P, et al. (2001) A randomized double-blind trial of intravenous trimetazidine as adjunctive therapy to primary angioplasty for acute myocardial infarction. Int J Cardiol 77:263-273.
35. Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215-262.
36. Tian R (2003) Transcriptional regulation of energy substrate metabolism in normal and hypertrophied heart. Curr Hypertens Rep 5:454-458.
37. Vincent G, Khairallah M, Bouchard B, and Des Rosiers C (2003) Metabolic phenotyping of the diseased rat heart using 13C-substrates and ex vivo perfusion in the working mode. Mol Cell Biochem 242:89-99.
38. Wambolt RB, Grist M, Bondy GP, and Allard MF (2001) Accelerated glycolysis and greater postischemic dysfunction in hypertrophied rat hearts are independent of coronary flow. Can J Cardiol 17:889-894.
39. Wambolt RB, Henning SL, English DR, Dyachkova Y, Lopaschuk GD, and Allard MF (1999) Glucose utilization and glycogen turnover are accelerated in hypertrophied rat hearts during severe low-flow ischemia. J Mol Cell Cardiol 31:493-502.
40. Wambolt RB, Lopaschuk GD, Brownsey RW, and Allard MF (2000) Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 36:1378-1385.